Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy targeting cluster of differentiation (CD)19 has had a transformative impact on patient outcomes in a subset of patients with relapsed/refractory non-Hodgkin lymphoma. We present a patient with refractory large B-cell lymphoma in complete remission for 2 years following treatment with CD19-targeted CAR T-cell therapy, who presented with 2 weeks of progressive aphasia. Imaging revealed a left occipital brain lesion and biopsy demonstrated features diagnostic of progressive multifocal leukoencephalopathy. Further evaluation revealed severe hypogammaglobulinemia and a low CD4 count. She was treated with pembrolizumab and intravenous immunoglobulin resulting in decreased cerebrospinal fluid viral load without clinical improvement and died 8 weeks after presentation. This case highlights that there is potential for severe opportunistic infections after CAR T-cell therapy, including fatal progressive multifocal leukoencephalopathy. Strategies to enhance post-treatment immune reconstitution are essential to further harness the unique potency of CAR T-cell therapy.

[1]  A. Weathers,et al.  Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy , 2021, European journal of haematology.

[2]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[3]  L. Lekakis,et al.  Progressive multifocal leukoencephalopathy after CAR T therapy , 2020, International Journal of Hematology.

[4]  M. Bar,et al.  Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Tuccori,et al.  Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab , 2019, Reviews in medical virology.

[6]  Bryan R. Smith,et al.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.

[7]  C. June,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[8]  L. Ramos-Duran,et al.  The Benefit of Mirtazapine in the Treatment of Progressive Multifocal Leukoencephalopathy in a Young HIV-positive Patient: A Case Report. , 2018, Innovations in clinical neuroscience.

[9]  M. Pulsipher,et al.  Hypogammaglobulinemia due to CAR T-cell therapy , 2017, Pediatric blood & cancer.

[10]  D. Maloney,et al.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. , 2017, Blood.

[11]  C. Atzori,et al.  Clearance of Cerebrospinal Fluid JCV DNA with Mirtazapine in a Patient with Progressive Multifocal Leukoencephalopathy and Sarcoidosis , 2016, Antiviral therapy.

[12]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[13]  I. Koralnik,et al.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.